Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Liver Diseases

Free Subscription 24.11.2025 1 AJR Am J Roentgenol 2 Am J Gastroenterol 5 Biochem Biophys Res Commun 2 BMC Cancer 5 BMC Gastroenterol 2 Dig Dis Sci 3 Eur Radiol 3 Gastroenterology 1 Gut 2 Hepatology 3 J Gastroenterol 2 J Gastroenterol Hepatol 7 J Hepatol 2 J Pediatr Surg 1 Lancet 1 Minerva Gastroenterol (Torino) 1 Oncogene 1 PLoS Comput Biol 5 PLoS One 1 Pol J Radiol 1 Proc Natl Acad Sci U S A 1 Radiol Imaging Cancer 1 Transplant Proc 2 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. DO RKG
   Identifying Earlier Surgical Margin Recurrence in Patients With Hepatocellular Carcinoma Using LI-RADS Treatment Response Assessment.
   AJR Am J Roentgenol. 2025 Nov 19. doi: 10.2214/AJR.25.34215.
   PubMed        
   
   

   
   Am J Gastroenterol

2. SMITH L, Sciacca K, Durieux BN, Bizup G, et al
   Harnessing Natural Language Processing to Identify Documentation of Serious Illness Communication for Patients with Decompensated Cirrhosis.
   Am J Gastroenterol. 2025 Nov 14. doi: 10.14309/ajg.0000000000003830.
   PubMed         Abstract available
   
   
3. SWAIN LA, Godley J, Wang M, Brahmania M, et al
   Temporal and demographic trends in alcohol-related-cirrhosis, alcohol-related hepatitis, and non-alcohol-related cirrhosis hospitalizations from 2012-2023: A population-based study in Alberta, Canada.
   Am J Gastroenterol. 2025 Nov 14. doi: 10.14309/ajg.0000000000003835.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

4. ZHOU R, Li Y, Luo L, Wang L, et al
   Deciphering the pharmacological mechanisms of Scutellariae Radix on hepatocellular carcinoma by combining network pharmacology, metabolomics and experimental evaluations.
   Biochem Biophys Res Commun. 2025;792:152918.
   PubMed         Abstract available
   
   
5. DONG M, Zhang J, Long L, Wang H, et al
   Establishment of a liver-specific Albumin-Cre recombinase transgenic golden hamster model using gRosa26-Targeted dual-fluorescent reporter system for hepatocyte-specific genetic manipulation.
   Biochem Biophys Res Commun. 2025;792:152912.
   PubMed         Abstract available
   
   
6. CHEN M, Yao J, Liu Z
   Curcumin ameliorates high-glucose-induced lipid accumulation in HepG2 cells via AMPK activation and mTOR suppression.
   Biochem Biophys Res Commun. 2025;790:152879.
   PubMed         Abstract available
   
   
7. SINGH A, Gupta I, Saha P, Hole A, et al
   Raman spectroscopy for detecting gastric and liver cancer cells that entered a tolerant persistence state to survive cisplatin chemotherapy.
   Biochem Biophys Res Commun. 2025;790:152891.
   PubMed         Abstract available
   
   
8. HU Y, Chai D, Geng Q, Chen L, et al
   Polyene phosphatidyl choline injection regulates lipid homeostasis via AKT-PDE3-PKA in mice.
   Biochem Biophys Res Commun. 2025;790:152921.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. ZHANG Y, Li W, Zhang W, Xing S, et al
   Low-dose radiotherapy combined with chemoimmunotherapy yields superior survival outcomes compared with chemoimmunotherapy alone for patients with small cell lung cancer with liver metastasis: a retrospective study.
   BMC Cancer. 2025;25:1785.
   PubMed         Abstract available
   
   
10. MA Y, Lou C, Liang J, Guo C, et al
    Characteristics of extracellular vesicle-derived lncRNAs during the progression of HBV-related hepatocellular carcinoma.
    BMC Cancer. 2025;25:1768.
    PubMed         Abstract available
    
    

    
    BMC Gastroenterol

11. ZHUANG Z, Zhuge F, Liu Y, Song Y, et al
    BIGH3 as a potential biomarker for fibrosis in metabolic dysfunction-associated steatotic liver disease: insights from mouse and human studies.
    BMC Gastroenterol. 2025;25:805.
    PubMed         Abstract available
    
    
12. MANSOUR A, Ebrahimi Mousavi S, Hemmati A, Hekmatdoost A, et al
    Resting energy expenditure in adults with nonalcoholic fatty liver disease and type 2 diabetes mellitus: comparison between measured and predicted values.
    BMC Gastroenterol. 2025;25:809.
    PubMed         Abstract available
    
    
13. LU H, Liang B, Zheng C, Xia X, et al
    Efficacy and safety analysis of D-TACE combined with lenvatinib in the treatment of hepatocellular carcinoma refractory to C-TACE.
    BMC Gastroenterol. 2025;25:817.
    PubMed         Abstract available
    
    
14. ASGHARI P, Ahmadi-Khorram M, Hatami A, Talebi S, et al
    Therapeutic potential of Akkermansia muciniphila in non-alcoholic fatty liver disease: a systematic review.
    BMC Gastroenterol. 2025;25:822.
    PubMed         Abstract available
    
    
15. ZHOU Y, He C, Zhang H
    Correlation study of fatty pancreas and fatty liver CT manifestations with biochemical parameters in middle-aged and young adult cholecystectomy patients.
    BMC Gastroenterol. 2025;25:824.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

16. KUMAR S, Lahooti A, Hajifathalian K, Critelli B, et al
    Prospective, Matched Case-Control Study of Endoscopic Sleeve Gastroplasty and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease at One Year.
    Dig Dis Sci. 2025;70:3922-3928.
    PubMed         Abstract available
    
    
17. KADRI R, Ma M, Montano-Loza A, Moctezuma-Velazquez C, et al
    Performance of RETREAT Score in a Liver Transplant Program That Follows Total Tumor Volume Criteria.
    Dig Dis Sci. 2025 Jun 27. doi: 10.1007/s10620-025-09191.
    PubMed         Abstract available
    
    

    
    Eur Radiol

18. CHOI SJ, Shin JI, Kim PH, Park HJ, et al
    MRI major and ancillary features of LI-RADS for diagnosis of pediatric malignant liver tumors.
    Eur Radiol. 2025;35:7688-7700.
    PubMed         Abstract available
    
    
19. KIM H, Kim B, Son SH, Jang JW, et al
    Evaluation of the LI-RADS radiation treatment response assessment v2024 in comparison with the modified RECIST.
    Eur Radiol. 2025;35:7549-7559.
    PubMed         Abstract available
    
    
20. ZHENG H, Liu Q, Wu N, Wu Z, et al
    Ablation for hepatocellular carcinoma in hepatitis B-related recompensated vs. compensated cirrhosis.
    Eur Radiol. 2025 Nov 14. doi: 10.1007/s00330-025-12135.
    PubMed         Abstract available
    
    

    
    Gastroenterology

21. DENG ZL, Safaei N, Schutte SL, Ohlendorf V, et al
    High Prevalence and Local Dissemination of Daptomycin-Resistance Mutations for Enterococcus faecium in Cirrhotic Patients.
    Gastroenterology. 2025 Nov 19:S0016-5085(25)06045.
    PubMed        
    
    
22. LI S, Zhong Y, Yang Y
    A rare etiology of hepatic steatosis.
    Gastroenterology. 2025 Nov 12:S0016-5085(25)06480.
    PubMed        
    
    
23. KIM NJ, Li M, Vutien P, Mecham B, et al
    Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening.
    Gastroenterology. 2025 Nov 14:S0016-5085(25)05906.
    PubMed         Abstract available
    
    

    
    Gut

24. SMETS L, Viola MF, Boesch M, Raman J, et al
    Intestinal blood vessel-associated macrophages and gut-vascular barrier dysfunction in cirrhosis.
    Gut. 2025 Nov 18:gutjnl-2025-335745. doi: 10.1136/gutjnl-2025-335745.
    PubMed         Abstract available
    
    

    
    Hepatology

25. PINTO E VAIRO F, Zimmermann MT, Wagenknecht J, Jorge SD, et al
    Discovery of a MET -driven monogenic cause of steatotic liver disease.
    Hepatology. 2025;82:1512-1522.
    PubMed         Abstract available
    
    
26. ZAPATA-PAVAS LE, Serrano-Macia M, Merlos Rodrigo MA, Barrenechea-Barrenechea JA, et al
    NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway.
    Hepatology. 2025 Nov 14. doi: 10.1097/HEP.0000000000001614.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

27. REN B, Li H, Liu S, Huang Z, et al
    Hic-5 deficiency attenuates MAFLD by inhibiting neutrophils migration via the CXCL1-CXCR2 axis.
    J Gastroenterol. 2025;60:1535-1553.
    PubMed         Abstract available
    
    
28. TSURUSAKI M, Sofue K, Murakami T, Tanigawa N, et al
    Evidence for imaging-based diagnosis of liver metastases from colorectal cancer.
    J Gastroenterol. 2025;60:1471-1480.
    PubMed         Abstract available
    
    
29. INADA H, Kurano S, Miyamoto H, Onishi M, et al
    TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2025 Nov 17. doi: 10.1007/s00535-025-02320.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

30. CHEN YC, Chang YP, Lee JY, Chen CY, et al
    Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2025 Nov 14. doi: 10.1111/jgh.70160.
    PubMed         Abstract available
    
    
31. ITO T, Shimose S, Saeki I, Takeuchi Y, et al
    Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2025 Nov 14. doi: 10.1111/jgh.70150.
    PubMed         Abstract available
    
    

    
    J Hepatol

32. LI R, Zhang J, Peng J, Zhang J, et al
    Divergent sex-specific trends in alcohol-attributable cirrhosis and liver cancer mortality: population-level insights complementing NHANES findings.
    J Hepatol. 2025 Nov 14:S0168-8278(25)02623-6. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
33. ENGEL B, Alaswad A, Campos-Murguia A, Zoodsma M, et al
    Molecular signatures discriminating different types of rejection in human liver transplants.
    J Hepatol. 2025 Jul 14:S0168-8278(25)02338-4. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
34. CHEN Y, Lee D, Kwan KK, Wu M, et al
    Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification.
    J Hepatol. 2025;83:1338-1352.
    PubMed         Abstract available
    
    
35. HANSEN CD, Hansen JK, Israelsen M, Andersen P, et al
    Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community.
    J Hepatol. 2025;83:1278-1291.
    PubMed         Abstract available
    
    
36. PENNISI G, Di Maria G, Wong VW, de Ledinghen V, et al
    Impact of first and further decompensation in patients with compensated ACLD due to MASLD.
    J Hepatol. 2025;83:1266-1277.
    PubMed         Abstract available
    
    
37. OH JH, Yoon EL, Park H, Lee S, et al
    Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2025;83:1256-1265.
    PubMed         Abstract available
    
    
38. DESCHLER S, Pohl-Topcu J, Ramsauer L, Meiser P, et al
    Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD.
    J Hepatol. 2025;83:1364-1378.
    PubMed         Abstract available
    
    

    
    J Pediatr Surg

39. PAKARINEN MP, Hukkinen M, Nyholm I, Lohi J, et al
    Decrease of post-portoenterostomy liver fibrosis in a nationally centralized cohort of biliary atresia patients.
    J Pediatr Surg. 2025 Aug 5:162505. doi: 10.1016/j.jpedsurg.2025.162505.
    PubMed         Abstract available
    
    
40. SCHWARZ D, Lam C, Davenport M
    Long-Term Reduction of Liver Fibrosis Surrogates In Syndromic Biliary Atresia.
    J Pediatr Surg. 2025 Sep 2:162626. doi: 10.1016/j.jpedsurg.2025.162626.
    PubMed        
    
    

    
    Lancet

41. NOUREDDIN M, Harrison SA, Loomba R, Alkhouri N, et al
    Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
    Lancet. 2025 Nov 11:S0140-6736(25)02114-2. doi: 10.1016/S0140-6736(25)02114.
    PubMed         Abstract available
    
    

    
    Minerva Gastroenterol (Torino)

42. ZHANG J, Wang X, Zhang P
    Peptidyl-prolyl isomerase A promotes migration and invasion of hepatoma cells by regulating Nrf2 and inhibiting ferroptosis.
    Minerva Gastroenterol (Torino). 2025 Nov 20. doi: 10.23736/S2724-5985.25.03964.
    PubMed         Abstract available
    
    

    
    Oncogene

43. CHEN W, Lin C, Wang L, Yu Z, et al
    Hepatitis B virus X protein promotes the progression and immune escape of hepatocellular carcinoma by activating KLF16-C12orf49-PD-L1 axis.
    Oncogene. 2025 Nov 14. doi: 10.1038/s41388-025-03625.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

44. SANCHEZ-BURGOS I, Tejedor AR, Collepardo-Guevara R, de la Serna JB, et al
    Molecular insights on the mechanism of alpha1-antitrypsin condensate formation and maturation.
    PLoS Comput Biol. 2025;21:e1013634.
    PubMed         Abstract available
    
    

    
    PLoS One

45. HUANG D, Zou H, Zhang Y
    Association of Framingham Steatosis Index with Albuminuria: A cross-sectional study.
    PLoS One. 2025;20:e0337104.
    PubMed         Abstract available
    
    
46. KAUSHAL K, Sharma MK, Aggarwal P, Singh S, et al
    Education as a predictor of liver testing behaviour: Insights from a large-scale MASLD awareness survey in India.
    PLoS One. 2025;20:e0335857.
    PubMed         Abstract available
    
    
47. INOUE A, Morimoto Y, Nishizawa Y, Hashimoto M, et al
    Clinical utility of circulating tumor DNA for early detection of recurrence after curative hepatectomy in patients with colorectal cancer with liver metastases: A prospective observational study protocol (CASSIOPEIA).
    PLoS One. 2025;20:e0335591.
    PubMed         Abstract available
    
    
48. LI Y, Liu T, Cai Z, Peng C, et al
    CXCL3 promotes liver cancer progression by modulating the tumor microenvironment via the PI3K/AKT/mTOR pathway.
    PLoS One. 2025;20:e0334639.
    PubMed         Abstract available
    
    
49. YU H, Kong D, Mo X, Huang J, et al
    MRI-based 2.5D deep learning and radiomics effectively predicted microvascular invasion and Ki-67 expression in hepatocellular carcinoma.
    PLoS One. 2025;20:e0336579.
    PubMed         Abstract available
    
    

    
    Pol J Radiol

50. DJURAYEVA N, Ikramov A, Babadzhanov A, Amirkhamzaev A, et al
    Portal hypertension of diverse origins: special features of hepatic haemodynamics based on perfusion computed tomography assessment.
    Pol J Radiol. 2025;90:e490-e497.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

51. WORMSER L, Fritz V, Kappelmann-Fenzl M, Rachinger N, et al
    The liver talks back: NPY orchestrates attraction of cancer cells and CHK2-dependent clonogenicity in the metastatic niche.
    Proc Natl Acad Sci U S A. 2025;122:e2518418122.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

52. DING W, Li B, Zhao L, Zheng L, et al
    Improving Detection of Intrahepatic Cholangiocarcinoma with a Contrast-enhanced US-based Deep Learning Model.
    Radiol Imaging Cancer. 2025;7:e250078.
    PubMed         Abstract available
    
    

    
    Transplant Proc

53. LI C, Sun Y, Din J, Cheng P, et al
    Predictive Value of Preoperative Serum Substance P Levels for Post-Transplant Recurrence in Patients With Hepatocellular Carcinoma.
    Transplant Proc. 2025 Nov 18:S0041-1345(25)00535.
    PubMed         Abstract available
    
    

    
    Transplantation

54. GILL M, Abhayaratna C, Brieger D, Huang J, et al
    Cirrhotic Cardiomyopathy Predicts New-onset Heart Failure Within the First Year After Liver Transplantation.
    Transplantation. 2025 Nov 17. doi: 10.1097/TP.0000000000005539.
    PubMed         Abstract available
    
    
55. CLARKE G, Mao J, Hann A, Fan Y, et al
    Evaluation of Liver Maximum Capacity Measurements to Monitor Hepatocellular Function During Extended Normothermic Machine Perfusion.
    Transplantation. 2025 Nov 17. doi: 10.1097/TP.0000000000005570.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.